Paper Details

  1. Home
  2. Paper Details

Adalimumab for maintenance of remission in Crohn's disease.

Author: AbbassMohamad, CepekJeremy, FeaganBrian G, JairathVipul, KhannaReena, MacDonaldJohn K, NguyenTran M, ParkerClaire E, TownsendCassandra M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Common treatments for Crohn's disease (CD) include anti-inflammatory drugs, medications that suppress the immune system, and steroids. If these don't work or stop working, biologic therapies like adalimumab (which blocks a substance called TNF-α) are used. Keeping CD under control is important because relapses can greatly affect quality of life.
Paper Details　
Original Abstract of the Article :
Conventional medications for Crohn's disease (CD) include anti-inflammatory drugs, immunosuppressants and corticosteroids. If an individual does not respond, or loses response to first-line treatments, then biologic therapies such as tumour necrosis factor-alpha (TNF-α) antagonists such as adalimuma...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7386457/

データ提供：米国国立医学図書館（NLM）

Adalimumab: A Beacon of Hope in the Desert of Crohn's Disease

Crohn's disease (CD) is a chronic inflammatory bowel disease, like a relentless sandstorm that can affect the digestive system. This review explores the use of adalimumab, a TNF-α antagonist, for maintaining remission in CD. It is like finding a source of water in the desert, offering a potential respite from the relentless storm.

Navigating the Sands: Maintaining Remission in Crohn's Disease

Maintaining remission in CD is a crucial goal for patients, as relapse can significantly impact their quality of life. This is like finding a stable path through the shifting sands of the desert, providing a sense of safety and security. Adalimumab has shown promise in achieving this goal, offering a potential oasis of relief for patients with CD.

A New Path Forward: Biological Therapies in Crohn's Disease

This review emphasizes the importance of biological therapies, such as adalimumab, for treating CD. It is like discovering a new route through the desert, offering a more effective and sustainable way to manage the disease. By understanding the mechanisms of action and efficacy of these therapies, we can better navigate the challenging terrain of CD and improve patient outcomes.

Dr. Camel's Conclusion

This review highlights the promise of adalimumab for maintaining remission in Crohn's disease. It offers a beacon of hope for patients seeking relief from the chronic inflammation and discomfort associated with CD. This research is like finding a new oasis in the desert, providing a source of water and resources for those struggling with this challenging condition.
Date :
  1. Date Completed 2020-09-11
  2. Date Revised 2022-09-24
Further Info :

Pubmed ID

32413933

DOI: Digital Object Identifier

PMC7386457

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.